High-molecular-weight adiponectin does not predict cardiovascular events in patients with type 2 diabetes

• Published in: Translational research : the journal of laboratory and clinical medicine 2009-04, Vol.153 (4), p.199-203
• Main Authors: Krzyzanowska, Katarzyna, Aso, Yoshimasa, Mittermayer, Friedrich, Inukai, Toshihiko, Brix, Johanna, Schernthaner, Guntram
• Format: Article
• Language: English
• Subjects: Adiponectin - blood; Adiponectin - chemistry; Biological and medical sciences; Cardiovascular Diseases - blood; Cardiovascular Diseases - complications; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2 - complications; Female; General aspects; Humans; Internal Medicine; Investigative techniques, diagnostic techniques (general aspects); Longitudinal Studies; Male; Medical sciences; Molecular Weight
• ISSN: 1931-5244; 1878-1810
• DOI: 10.1016/j.trsl.2009.01.009

Low circulating high-molecular-weight (HMW) adiponectin might be associated with increased cardiovascular risk. This study aimed to investigate the relationship between HMW adiponectin and cardiovascular events in patients with type 2 diabetes mellitus (T2DM) with an adverse cardiovascular risk profile. The investigation took place in a specialized outpatient clinic for metabolic diseases and included 147 patients with T2DM following a cross-sectional and a prospective study protocol. Ninety patients had macrovascular disease at baseline defined as preexisting coronary artery disease, previous stroke, or peripheral artery disease. HMW adiponectin measured by enzyme-linked immunosorbent assay (Fujirebio, Tokyo, Japan) and routine clinical parameters were determined in all patients at baseline. The occurrence of new cardiovascular events (myocardial infarction, stroke, and all-cause mortality) during the follow-up period was evaluated. No significant correlations between traditional cardiovascular risk markers and HMW adiponectin could be detected. HMW adiponectin did not differ between subjects with and without macrovascular disease at baseline (3.5 [interquartile range [IQR]: 2.2–5.7] mg/L vs 4.0 [IQR: 2.5–7.1] mg/L). During a follow-up of 19.3 (IQR: 16–25) months, 61 endpoints (41 myocardial infarctions, 10 strokes, and 10 deaths) were observed. A 1-standard-deviation increment of log-transformed HMW adiponectin was not significantly associated with the occurrence of cardiovascular events (Adjusted hazard ratio [HR]: 0.95; 95% confidence interval [CI]: 0.58–1.54; P = 0.835). In conclusion, HMW adiponectin was not related to present macrovascular disease and is not associated with future cardiovascular events in high-risk patients with T2DM. It is unlikely that HMW adiponectin has significant vasoprotective effects in these patients.